NEW YORK (GenomeWeb) – Wells Fargo Securities today upgraded shares of Bruker to an Outperform rating and increased the price range on its stock after a Bruker official said the company plans to further restructure its Chemical and Applied Markets division and grow its presence in the clinical market.

Analyst Tim Evans upgraded Bruker from a previous Market Perform rating and raised the price range on Bruker's shares to between $25 and $27 from an earlier range of $21 to $22.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.